HNF1B and ovarian clear cell cancer: HNF1β overexpression in breast cancer34 and pancreatic clear cell carcinoma35 also correlates with worse survival rates, and the developed constrained peptide inhibitors may have a therapeutic effect on breast, pancreatic, and ovarian clear cell carcinoma proliferation.36 This method of rational design of constrained‐peptide drug candidates should also be applicable to other IDDs.